Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 4.4% – What’s Next?

Posted by Latisha Jones on Oct 21st, 2026

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) shares traded down 4.4% on Monday. The company traded as low as $0.45 and last traded at $0.45. 33,977 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 313,814 shares. The stock had previously closed at $0.4705.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Reviva Pharmaceuticals presently has an average rating of “Hold” and an average price target of $53.33.

View Our Latest Research Report on RVPH

Reviva Pharmaceuticals Trading Down 5.5%

The company has a market cap of $5.70 million, a P/E ratio of -0.23 and a beta of 0.48. The company’s 50-day moving average price is $0.50 and its two-hundred day moving average price is $0.58.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.19. As a group, analysts anticipate that Reviva Pharmaceuticals Holdings, Inc. will post -2.96 earnings per share for the current year.

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system, cardiometabolic and inflammatory disorders. The company’s research is based on compounds designed to modulate serotonin and dopamine receptors, which are involved in multiple neurological and psychiatric conditions.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational, once-daily small molecule being developed primarily for schizophrenia and other potential neuropsychiatric indications.